A psychedelic drug candidate from Helus Pharma significantly helped people with major depression in a Phase 3 trial, the company said Monday, but a number of serious adverse events in the study raised questions about the safety of the treatment.
At six weeks, people taking the drug in addition to their standard antidepressants experienced a reduction of 19.5 points on a depression rating scale called the MADRS, while the placebo group had a 11.9-point reduction.
At 12 weeks, the effect was largely maintained, with the treatment group seeing a 16.9-point reduction and the placebo group experiencing a 9.9-point reduction. The differences between the two groups were all statistically significant.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Source: www.statnews.com



